Reduction of exacerbations by the PDE4 inhibitor roflumilast - the importance of defining different subsets of patients with COPD

<p>Abstract</p> <p>Background</p> <p>As chronic obstructive pulmonary disease (COPD) is a heterogeneous disease it is unlikely that all patients will benefit equally from a given therapy. Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, has been shown to...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Goehring Udo M, Calverley Peter MA, Rennard Stephen I, Bredenbröker Dirk, Martinez Fernando J
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BMC 2011-01-01
Seri Bilgileri:Respiratory Research
Online Erişim:http://respiratory-research.com/content/12/1/18
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller